Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma: a Multicenter, Prospective, Observational Cohort Study

NCT07340502 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07340502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07340502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma: a Multicenter, Prospective, Observational Cohort Study
Lead sponsor
Tongji Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
December 31, 2028
Enrollment
364 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hcc